Again, don’t make the mistake of assuming $HIMS is a peptide company, as the market did with GLP-1s. Peptides have upside, but healthcare broadly has infinite upside. The value for $HIMS is in growing the D2C infra and using it to train the world’s top AI model. Focus on value.
View on X ↗